Journey Medical Corp Enters New Sales Agreement

The latest announcement is out from Journey Medical Corp ( (DERM) ).

On August 28, 2025, Journey Medical Corporation entered into a new At Market Issuance Sales Agreement with B. Riley Securities, Inc. and Lake Street Capital Markets, LLC, allowing the company to sell up to 3,750,000 shares of its common stock. This agreement follows the termination of a previous sales agreement with B. Riley, under which the company sold 4,121,318 shares from December 30, 2022, to August 28, 2025. The new agreement, which includes customary terms and conditions, aims to provide Journey Medical with flexibility in raising capital, potentially impacting its financial strategy and market positioning.

The most recent analyst rating on (DERM) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Journey Medical Corp stock, see the DERM Stock Forecast page.

Spark’s Take on DERM Stock

According to Spark, TipRanks’ AI Analyst, DERM is a Neutral.

Journey Medical Corp’s overall stock score is primarily impacted by its financial challenges, including declining revenues and negative profitability. However, the successful launch of EMROSI and positive corporate events provide some optimism. Technical indicators suggest a mixed outlook, with short-term bearish trends but medium-term support. Valuation remains a concern due to negative earnings and lack of dividends.

To see Spark’s full report on DERM stock, click here.

More about Journey Medical Corp

Journey Medical Corporation operates in the medical industry, focusing on the development and commercialization of pharmaceutical products. The company primarily offers dermatological treatments and is engaged in expanding its market presence through strategic agreements.

Average Trading Volume: 163,583

Technical Sentiment Signal: Buy

Current Market Cap: $180.9M

For detailed information about DERM stock, go to TipRanks’ Stock Analysis page.